Product image of Meliglix (Sitagliptin) supplied by GNH India

Meliglix

Active Ingredient:
Sitagliptin
Origin:
EU

Meliglix (Sitagliptin)

Sitagliptin, the active ingredient in Meliglix, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise.

GNH India supplies Meliglix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Pharmazac Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meliglix (sitagliptin) belongs to the DPP‑4 inhibitor class and is employed in the management of type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: improves glycemic control when combined with diet and exercise.
  • Monotherapy in patients inadequately controlled by lifestyle alone: provides additional glucose lowering.
  • Combination therapy with other antidiabetic agents: enhances overall blood sugar management.

How It Works

  • Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 enzyme, which degrades the incretin hormones GLP‑1 and GIP. By preventing this degradation, endogenous incretin levels rise, leading to glucose‑dependent stimulation of insulin secretion and suppression of glucagon release, thereby lowering plasma glucose concentrations without causing hypoglycaemia in the absence of other agents.

Side Effects

Adverse reactions to sitagliptin are generally mild to moderate, but serious events can occur and require prompt medical attention.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Headache: transient cranial discomfort.
  • Nasopharyngitis: common cold‑like symptoms.
  • Upper respiratory tract infection: mild cough or sore throat.
  • Dizziness: occasional light‑headedness.
  • Hypoglycaemia (when used with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring urgent care.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Bullous pemphigoid: blistering skin disorder.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Severe joint pain: unexplained arthralgia.

Precautions & Warnings

Before initiating sitagliptin therapy, several safety considerations should be reviewed.

  • Renal impairment: dose adjustment may be required based on creatinine clearance.
  • Hepatic disease: monitor liver function tests regularly.
  • History of pancreatitis: avoid use due to potential recurrence.
  • Elderly patients: observe for signs of hypoglycaemia, especially when combined with other agents.
  • Pregnancy and lactation: safety not established; use only if clearly needed.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Sitagliptin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Insulin: increased risk of hypoglycaemia.
  • Sulfonylureas (e.g., glipizide): heightened hypoglycaemia potential.

Moderate Interactions (Monitor Closely)

  • Rifampin: may reduce sitagliptin plasma concentrations.
  • Diuretics (e.g., furosemide): can increase serum creatinine.
  • ACE inhibitors (e.g., lisinopril): monitor renal function and electrolytes.

Frequently Asked Questions

Meliglix contains sitagliptin, a DPP‑4 inhibitor indicated to improve blood glucose control in adults with type 2 diabetes mellitus, usually as part of a comprehensive plan that includes diet, exercise, and possibly other antidiabetic agents.

Sitagliptin blocks the DPP‑4 enzyme, which normally breaks down the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin release and reduces glucagon secretion, leading to lower blood sugar levels.

The specific dose of Meliglix is determined by the prescribing healthcare professional based on individual patient factors such as renal function, concomitant medications, and glycaemic targets. Patients should follow the prescriber’s instructions.

The safety of sitagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified clinician.

To request Meliglix, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower intrinsic risk of hypoglycaemia because it enhances insulin secretion only when glucose is elevated. Unlike metformin, it does not affect gastrointestinal absorption and is generally well tolerated, but it does not provide the same weight‑loss benefit.

Meliglix tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Meliglix is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should not crush or chew the tablet unless specifically instructed by a healthcare professional.

Serious adverse events include pancreatitis, severe allergic reactions such as anaphylaxis, bullous pemphigoid, and rare cases of hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or unexplained joint pain.

Meliglix is contraindicated in patients with a known hypersensitivity to sitagliptin or any of its excipients. It should be used with caution in individuals with a history of pancreatitis, severe renal impairment, or significant hepatic disease, and it is not recommended for pregnant or breastfeeding women without specialist advice.

Medically reviewed by

Dr. Shweta Ashok More

M.Pharm (Quality Assurance), Ph.D. (Medicinal Chemistry), GNH India Pharmaceuticals Limited · Reviewed 9 Sep 2026

Published by GNH India Pharmaceuticals Limited · Last updated

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT